The Institute for Gene Therapies is a Washington, D.C.-based nonprofit advocacy group focused on gene therapy. It lobbies Congress and federal agencies about rules and payment policies for new gene therapies, including how they are regulated and reimbursed by insurers and government programs. It has reported $250,000 in lobbying across five filings and uses Thorn Run Partners for lobbying work.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
ANDY ROSENBERG
The latest disclosures for this client.
THORN RUN PARTNERS
Q2THORN RUN PARTNERS
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
THORN RUN PARTNERS
BEAU SCHUYLER
THORN RUN PARTNERS
THORN RUN PARTNERS
Q1THORN RUN PARTNERS
Q4THORN RUN PARTNERS
Q3THORN RUN PARTNERS
2ATHORN RUN PARTNERS
Q2THORN RUN PARTNERS
Q1